Related Experiment Video

Updated: Jun 18, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer

R Jing1, M Cui, J Wang

  • 1Center of Laboratory Medicine, Affiliated Hospital of Nantong University, Affiliated Hospital of Nantong University, 20 Xi Si Road, Nantong 226001, PR China. jrjr2020@163.com

Neoplasma
|November 10, 2009
PubMed
Abstract

Insights

Serum levels of soluble Receptor for Advanced Glycation End products (sRAGE) are decreased in lung cancer patients. This decrease in sRAGE may indicate reduced RAGE expression and suggests sRAGE as a potential diagnostic biomarker for lung cancer.

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Receptor for Advanced Glycation End products (RAGE) plays a role in cancer progression.
  • Soluble RAGE (sRAGE) physiologically inhibits RAGE-mediated pathological effects.
  • Understanding sRAGE and RAGE expression is crucial for lung cancer research.

Purpose of the Study:

  • To investigate the expression profile of sRAGE and RAGE in lung cancer patients.
  • To determine the potential of sRAGE as a diagnostic biomarker for lung cancer.

Main Methods:

  • Serum sRAGE levels were quantified using ELISA in 45 individuals.
  • RAGE expression in lung cancer tissue was analyzed via immunohistochemistry in 28 patients.
  • Statistical analysis was performed to correlate sRAGE levels with clinical parameters.

Main Results:

  • Serum sRAGE levels were significantly lower in lung cancer patients compared to healthy donors and tuberculosis patients (P=0.034, P=0.010).
  • Lower sRAGE concentration correlated with advanced lymph node involvement (N0 vs. N1-2, P=0.028).
  • RAGE expression was downregulated in lung cancer tissue compared to normal lung tissue, with correlations observed between serum sRAGE and tissue RAGE expression.

Conclusions:

  • Serum sRAGE levels decrease during lung cancer progression.
  • Decreased sRAGE may reflect reduced RAGE expression in lung tissues.
  • Serum sRAGE shows potential as an effective and convenient diagnostic biomarker for lung cancer.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...